Clinical Trials Logo

Filter by:
NCT ID: NCT05807217 Recruiting - Sepsis Clinical Trials

A Pharmacokinetics Study of Meropenem and Piperacillin in Patients With Sepsis

APSOMAPIPWS
Start date: October 26, 2022
Phase:
Study type: Observational

This study was a single-center, open clinical study in Chinese septic patients with or without acute kidney injury. The aims of this study were to obtain the blood concentration and pharmacokinetic parameters of meropenem and piperacillin, exosome information and endogenous biomarker, and to explore the functional changes of OATs under the condition of sepsis and acute kidney injury.

NCT ID: NCT05806736 Recruiting - Parkinson Disease Clinical Trials

Curative Effect and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation on Non-motor Symptoms of PD

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This study is a double-blind comparative study examining the curative effect and mechanism of the transcutaneous auricular vagus nerve stimulation treatment on non-motor symptoms of Parkinson's disease patients. The investigators hypothesize that treatment using transcutaneous auricular vagus nerve stimulation will improve the non-motor symptoms, such as improving sleep, and improve cortical activity simultaneously in Parkinson's disease patients.

NCT ID: NCT05806671 Not yet recruiting - Breast Cancer Clinical Trials

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Start date: May 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the triplet combination of dalpiciclib, fulvestrant, and pyrotinib is safe and effective in the treatment of hormone receptor-positive, HER2-low locally advanced/metastatic breast cancer following treatment with an aromatase inhibitor plus a CDK4/6 inhibitor (palbociclib abemaciclib or ribociclib). The study will employ a Bayesian Optimal Phase II (BOP2) design which explicitly controls the type I error rate, thereby bridging the gap between Bayesian designs and frequentist designs, and has favorable operating characteristics with higher power and lower risk of incorrectly terminating the trial than some existing Bayesian phase II designs.

NCT ID: NCT05806580 Recruiting - Clinical trials for Relapsed or Refractory B-cell Lymphoma

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Start date: May 1, 2022
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of post-marketing Regiorense injection secondary infusion in the treatment of adult patients with relapsed or refractory B-cell lymphoma.

NCT ID: NCT05806333 Recruiting - Liver Cancer Clinical Trials

[18F]FAPI PET/CT in Suspicious Focal Liver Lesions Without FDG Avidity

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Fibroblast activation protein (FAP) is a serine protease that belongs to the dipeptidyl peptidase-IV (DPP-IV) family located in fbroblast membranes. FAP is overexpressed in the cancer-associated fbroblasts (CAFs) of 90% of epithelial carcinomas, including primary and metastatic liver cancer. We aim to conduct a prospective study to investigate the diagnostic perfoemance of 18F-FAPI PET/CT in evaluating suspicious liver mass without FDG avidity.

NCT ID: NCT05806281 Not yet recruiting - Emotional Distress Clinical Trials

The Role of Cognitive Flexibility in Mindfulness Intervention for Emotional Distress

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

This study hopes to: 1. explore whether offline and online mindfulness interventions can significantly alleviate individual emotional distress and improve cognitive flexibility level. 2. explore whether cognitive flexibility is a mediator in mindfulness intervention to alleviate emotional distress, and to meet the principles of mechanism.

NCT ID: NCT05806177 Completed - Alzheimer Disease Clinical Trials

Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects

MAD
Start date: May 26, 2020
Phase: Phase 1
Study type: Interventional

This single-center, randomized, placebo-controlled, double-blind, dose-increasing study was designed to evaluate the safety, tolerability, and pharmacokinetics of multiple successive dosing in healthy Chinese adult subjects.In this study, 20 healthy adult subjects were enrolled in a multi-dose study in the 30mg and 40mg groups.

NCT ID: NCT05806125 Recruiting - Cervical Cancer Clinical Trials

Clinical Value of the Fertility-preserving Surgery in Cervical Cancer

Start date: January 1, 2023
Phase:
Study type: Observational

Purpose: To evaluate the clinical value of preserving the ascending branch of the uterine artery in improving the uterine blood supply after radical trachelectomy (RT). Method: This study will include 100 patients with early-stage cervical cancer, who undergo RT with the preservation of the ascending branch of the uterine artery. A new skill called the "cuff-sleeve" suture method is introduced to wrap the vagina around the stump cervix, wherein they are sutured using a 2-0 absorbable suture by placing two cross-stitches in the anterior and posterior wall, respectively, without piercing the cervical mucosa layer or damaging the uterine arteries. Study groups: The patients will be categorized into two groups. Patients in the postoperative group will undergo computed tomography angiography (CTA) after surgery and patients in the preoperative group will undergo CTA before RT. Data collection: Data regarding individual patient characteristics, International Federation of Gynecology and Obstetrics (FIGO) stage, histologic subtype, lymphovascular space involvement (LVSI) status, recurrence, CTA data, fertility results, and obstetric outcomes will be collected for the patients in the postoperative group. The CTA findings of the preoperative group will be obtained. Statistical methods: Statistical analyses were performed using IBM SPSS Statistics, version 26. The t-test is used for analyzing the continuous variables and the chi-squared test for categorical variables.

NCT ID: NCT05806099 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

Start date: June 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered by intravenous (IV) infusion in participants with relapsed or refractory B-cell NHL. This entry-to-human study consists of 2 parts: a dose escalation part (Phase I) and an expansion part (Phase Ⅱ)

NCT ID: NCT05806086 Completed - Otologic Disease Clinical Trials

Clinical Effect of Panfoxol of Otolaryngological Diseases of Upper Respiratory Tract Infection: A Multicenter Retrospective Observational Study

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Patients with otolaryngological diseases caused by upper respiratory tract infections, including allergic rhinitis, chronic rhinosinusitis, secretory otitis media, and oblate gland hypertrophy, were treated with all drugs from Sun Yat-sen Memorial Hospital of Sun Yat-sen University, the First Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial People's Hospital, and Guangdong Provincial Hospital of Traditional Chinese Medicine from January 2021 to December 2022. According to the treatment methods, the patients were divided into panfosol + conventional treatment group and conventional treatment group for multicenter retrospective analysis.